nach oben

Wiener klinische Wochenschrift

Erschienen in:

06.07.2022 | original article

Prognostic assessment of C‑reactive protein and neutrophil to lymphocyte ratio in patients with non-small cell lung cancer

verfasst von: Tingting Zhao, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2022

Einloggen, um Zugang zu erhalten

Summary

Objective

To investigate the prognostic assessment of inflammatory factor serum C‑reactive protein CRP and neutrophil to lymphocyte ratio NLR value in patients with non-small cell lung cancer NSCLC.

Methods

A retrospective analysis was conducted for 475 patients with NSCLC who visited our hospital with complete follow-up data from January 2017 to 1 January 2019. The changes of serum CRP, NLR levels in patients with NSCLC of different stages, as well as the changes in the levels of the two indexes before and after chemotherapy in patients with advanced stage were compared using t tests with SPSS19.0 software. Serum CRP and NLR were divided into low and high groups with median intercept values and the relationship between inflammation score index and tumor progression-free survival time (PFS) was analyzed retrospectively. Clinical factors that may affect disease prognosis were included in the proportional hazards (COX) regression model for multifactorial prognostic analysis.

Results

Pretreatment serum levels of NLR and CRP were significantly higher in non-operated patients relative to preoperative levels in surgical patients. Advanced patients had higher levels of both indexes than locally advanced patients. After chemotherapy, the levels of the two indexes reaching remission were significantly lower than those before chemotherapy. The levels of the two indexes in patients with stable disease after chemotherapy were not statistically significant compared with those before chemotherapy, and the levels of the two indexes in the group with progressive disease after chemotherapy were significantly higher than those before chemotherapy. The results of PFS survival analyses showed that PFS was prolonged in the low score CRP and the low score NLR group, compared with the high score group. Multifactorial prognostic analysis showed that smoking, CRP and NLR were risk factors for PFS prognosis in patients with NSCLC.

Conclusion

Serum CRP and NLR are effective predictors of poor prognosis in patients with NSCLC.

Vorheriger Artikel Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe

Nächster Artikel 46. Jahrestagung der Österreichischen Gesellschaft für Pneumologie 6. Jahrestagung der Österreichischen Gesellschaft für Thoraxchirurgie

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.PubMedCrossRef

Zhou C, Wang J, Wang B, Cheng Y, Wang Z, Han B, Lu Y, Wu G, Zhang L, Song Y, Zhu B, Hu Y, Wang Z, Song Q, Ren S, He Y, Hu X, Zhang J, Yao Y, Zhao H, Wang Z, Chu Q, Duan J, Liu J, Qin S. Lung cancer: a review. Chin J Lung Cancer. 2021;24(04):217–35.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.PubMedCrossRef

Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121–6.PubMedPubMedCentralCrossRef

Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, inflammation and colorectal cancer. Cells. 2020;9(3):618.PubMedCentralCrossRef

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef

Tajan M, Vousden KH. Dietary approaches to cancer therapy. Cancer Cell. 2020;37(6):767–85.PubMedCrossRef

Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B, Yang W. Prognostic value of C‑reactive protein in patients with Coronavirus 2019. Clin Infect Dis. 2020;71(16):2174–9.PubMedCrossRef

Wu CC, Li SH, Lu HI, Lo CM, Wang YM, Chou SY, Chen YH. Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: a propensity score-matched analysis. PeerJ. 2018;6:e5655.PubMedPubMedCentralCrossRef

10.

Arima K, Yamashita YI, Hashimoto D, Nakagawa S, Umezaki N, Yamao T, Tsukamoto M, Kitano Y, Yamamura K, Miyata T, Okabe H, Ishimoto T, Imai K, Chikamoto A, Baba H. Clinical usefulness of postoperative C‑reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Am J Surg. 2018;216(1):111–5.PubMedCrossRef

11.

Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264–79.PubMedCrossRef

12.

Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut. 2021;70(1):204–14.PubMedCrossRef

13.

Graziano V, Grassadonia A, Iezzi L, Vici P, Pizzuti L, Barba M, Quinzii A, Camplese A, Di Marino P, Peri M, Veschi S, Alberti S, Gamucci T, Di Gioacchino M, De Tursi M, Natoli C, Tinari N. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients. Breast. 2019;44:33–8.PubMedCrossRef

14.

Zhou J, Diao X, Wang S, Yao Y. Diagnosis value of combined detection of serum SF, CEA and CRP in non-small cell lung cancer. Cancer Manag Res. 2020;12:8813–9.PubMedPubMedCentralCrossRef

15.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176–81.PubMedCrossRef

16.

Kato K, Hitsuda Y, Kawasaki Y, Igishi T, Yasuda K, Mikami M, Watanabe M, Miyata M, Sasaki T, Shimizu E. The value of serum C‑reactive protein as a survival determinant in patients with advanced non-small-cell lung cancer. Nihon Kokyuki Gakkai Zasshi. 2000;38(8):575–80.PubMed

17.

Koh YW, Lee HW. Prognostic impact of C‑reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy. Medicine. 2017;96(19):e6848.PubMedPubMedCentralCrossRef

18.

Bharadwaj U, Kasembeli MM, Robinson P, Tweardy DJ. Targeting Janus kinases and signal transducer and activator of transcription 3 to treat inflammation, fibrosis, and cancer: rationale, progress, and caution. Pharmacol Rev. 2020;72(2):486–526.PubMedPubMedCentralCrossRef

19.

Okada S, Shimomura M, Tsunezuka H, Teramukai S, Ishihara S, Shimada J, Inoue M. Prognostic significance of perioperative C‑reactive protein in resected non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2020;32(4):1046–55.PubMedCrossRef

20.

Sinha A, Sharma MK, Tripathi K, Duggal N, Tiwari VK. Evaluation of serum levels of procalcitonin and C‑reactive protein as prognostic indicators in burns. Indian J Plast Surg. 2021;54(3):308–13.PubMedPubMedCentralCrossRef

21.

Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K. Serological risk index based on alpha-fetoprotein and C‑reactive protein to indicate futile liver transplantation among patients with advanced hepatocellular carcinoma. Dig Dis Sci. 2019;64(1):269–80.PubMedCrossRef

22.

Ietomi K. A study on the role of granulocytes in carcinoma-bearing hosts—G/L ratio as a new host indicator. Nihon Gan Chiryo Gakkai Shi. 1990;25(3):662–71.PubMed

23.

Sun S, Qu Y, Wen F, Yu H. Initial neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with inoperable locally advanced non-small-cell lung cancer. Biomark Med. 2020;14(14):1341–52.PubMedCrossRef

24.

Sebastian NT, Raj R, Prasad R, Barney C, Brownstein J, Grecula J, Haglund K, Xu-Welliver M, Williams TM, Bazan JG. Association of pre- and posttreatment neutrophil-lymphocyte ratio with recurrence and mortality in locally advanced non-small cell lung cancer. Front Oncol. 2020;10:598873.PubMedPubMedCentralCrossRef

25.

Takamori S, Tagawa T, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Honda H, Maehara Y. Prognostic impact of postoperative skeletal muscle decrease in non-small cell lung cancer. Ann Thorac Surg. 2020;109(3):914–20.PubMedCrossRef

26.

Coelho NH, Coelho A, Augusto R, Semião C, Peixoto J, Fernandes L, Martins V, Canedo A, Gregório T. Pre-operative neutrophil to lymphocyte ratio is associated with 30 day death or amputation after revascularisation for acute limb ischaemia. Eur J Vasc Endovasc Surg. 2021;62(1):74–80.PubMedCrossRef

27.

Obermayr E, Braicu EI, Polterauer S, Loverix L, Concin N, Woelber L, Mahner S, Sehouli J, Van Gorp T, Vergote I, Zeillinger R, Aust S. Association of a combined cancer exhaustion score with circulating tumor cells and outcome in ovarian cancer—a study of the OVCAD consortium. Cancers (Basel). 2021;13(23):5865.CrossRef

28.

Hotta T, Nakashima K, Hata K, Tsubata Y, Isobe T. High serum C‑reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma. J Thorac Dis. 2021;13(3):1476–84.PubMedPubMedCentralCrossRef

29.

Svaton M, Blazek J, Krakorova G, Buresova M, Teufelova Z, Vodicka J, Hurdalkova K, Barinova M, Pesek M. Laboratory parameters are possible prognostic markers in patients with advanced-stage NSCLC treated with bevacizumab plus chemotherapy. J Cancer. 2021;12(19):5753–9.PubMedPubMedCentralCrossRef

30.

Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27–41.PubMedPubMedCentralCrossRef

31.

Ozel I, Duerig I, Domnich M, Lang S, Pylaeva E, Jablonska J. The good, the bad, and the ugly: neutrophils, angiogenesis, and cancer. Cancers (Basel). 2022;14(3):536.CrossRef

32.

Andina N, Bonadies N, Allam R. Inflammasome activation in myeloid malignancies-friend or foe? Front Cell Dev Biol. 2022;9:825611.PubMedPubMedCentralCrossRef

Titel: Prognostic assessment of C‑reactive protein and neutrophil to lymphocyte ratio in patients with non-small cell lung cancer
verfasst von: Tingting Zhao, MD
Publikationsdatum: 06.07.2022
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 19-20/2022
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-022-02049-4

Springer Medizin Österreich

Summary

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 19-20/2022

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update

MUW researcher of the month

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer

Wiener klinische Wochenschrift

Establishment of a virtual transborder tumor board for cancer patients in Central and Southeastern Europe

46. Jahrestagung der Österreichischen Gesellschaft für Pneumologie 6. Jahrestagung der Österreichischen Gesellschaft für Thoraxchirurgie